Literature DB >> 1899732

Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites.

L Chatenoud1, C Legendre, C Ferran, J F Bach, H Kreis.   

Abstract

The data presented extend to a larger series of 27 consecutive renal allograft recipients treated prophylactically with OKT3 our previous observation that the acute OKT3-induced clinical syndrome is related to massive release in the circulation of some cytokines, among which are tumor necrosis factor and interferon gamma. In addition, a pilot randomized study was set up including 12 consecutive patients receiving high-dose corticosteroid treatment (0.5 g solumedrol) either before or at the same time as the first OKT3 injection. Results confirm that when corticosteroids are given in sufficient amount and, importantly, 1 hr before the first OKT3 injection, they significantly decrease the release of both tumor necrosis factor and interferon gamma. In addition, the pretreatment with corticosteroids may totally abolish the IL-2 release induced by OKT3. Given the key role the massive although transient cytokine release plays in determining the OKT3-induced acute syndrome, these results provide the biological basis supporting a precise kinetics of administration of high-dose corticosteroids to better decrease the severity of the clinical reaction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899732     DOI: 10.1097/00007890-199102000-00012

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Immunosuppressive drugs in renal transplantation. A review of the regimens.

Authors:  J M Barry
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

2.  Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatment.

Authors:  G J Zlabinger; K M Stuhlmeier; R Eher; S Schmaldienst; R Klauser; A Vychytil; B Watschinger; O Traindl; J Kovarik; E Pohanka
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

Review 3.  New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.

Authors:  Hirofumi Ochi; Michal Abraham; Hiroki Ishikawa; Dan Frenkel; Kaiyong Yang; Alexandre Basso; Henry Wu; Mei-Ling Chen; Roopali Gandhi; Ariel Miller; Ruth Maron; Howard L Weiner
Journal:  J Neurol Sci       Date:  2008-09-18       Impact factor: 3.181

Review 4.  Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

5.  Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.

Authors:  C Ferran; F Dautry; S Mérite; K Sheehan; R Schreiber; G Grau; J F Bach; L Chatenoud
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

6.  In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.

Authors:  K J Parlevliet; I J ten Berge; S L Yong; J Surachno; J M Wilmink; P T Schellekens
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 7.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

Review 8.  Teplizumab therapy for type 1 diabetes.

Authors:  Umesh B Masharani; Joseph Becker
Journal:  Expert Opin Biol Ther       Date:  2010-03       Impact factor: 4.388

Review 9.  Harnessing Newton's third-law paradigm to treat autoimmune diseases and chronic inflammations.

Authors:  Tue Gia Nguyen
Journal:  Inflamm Res       Date:  2020-06-26       Impact factor: 6.986

Review 10.  Non-antigenic and antigenic interventions in type 1 diabetes.

Authors:  Anna K E Rydén; Johnna D Wesley; Ken T Coppieters; Matthias G Von Herrath
Journal:  Hum Vaccin Immunother       Date:  2013-10-28       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.